Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B

BMC Gastroenterology

Volumn 5, Issue , 2005, Pages

  Montazeri, Ghodrat ^a   Estakhri, Arezoo ^a   Mohamadnejad, Mehdi ^a,b   Nouri, Negin ^a   Montazeri, Farhad ^a   Mohamadkhani, Ashraf ^a   Derakhshan, Mohammad Hossein ^a   Zamani, Farhad ^a,b   Samiee, Shahram ^a   Malekzadeh, Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER; HEPATITIS B(E) ANTIGEN; HYALURONIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PATIENT MONITORING; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; VIROLOGY;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; HYALURONIC ACID; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 27644452222     PISSN: 1471230X     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-5-32     Document Type: Article

References (41)

1. Lee WM: Hepatitis B virus infection. N Engl J Med 1997, 337:1733-1745.
2. Kane M: Global programme for control of hepatitis B infection. Vaccine 1995, 13(Suppl 1): S5.
3. Mast EE, Alter MJ: Epidemiology of viral hepatitis: an overview. Sem Virol 1993, 4:273-283.
4. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER: Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105-117.
5. Phillips MG, Preedy VR, Hughes RD: Assessment of prognosis in alcoholic liver disease: can serum hyaluronate replace liver biopsy? Eur J Gastroenterol Hepatol 2003, 15:941-944.
6. Nord HJ: Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques - a review. Gastrointest Endosc 1982, 28:102-104.
7. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ: Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986, 1:523-525.
8. Piccinino F, Sagnelli E, Pasquale G, Giusti G: Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986, 2:165-173.
9. Cadranel JF, Rufat P, Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000, 32:477-481.
10. Quinn PG, Johnston DE: Detection of chronic liver disease: costs and benefits. Gastroenterologist 1997, 5:58-77.
11. Hayes PC, Bouchier IA: Liver function test in clinical practice: Their uses and limitations. Clin Chem Enzym Commun 1989, 2:23-24.
12. Chopra S, Griffin PH: Laboratory tests and diagnostic procedures in evaluation of liver disease. Am J Med 1985, 79:221-230.
13. Hayes PC, Thomas P, Bouchier IA, Piris J: Biochemistry and histology in chronic liver disease. Clin Chem Enzym Commun 1990, 3:245-250.
14. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, Gallois Y, Rifflet H, Maiga MY,Penneau-Fontbonne D, Cales P: Non-invasive diagnosis of hepatic fibrosis and cirrhosis. Gastroenterology 1997, 113-1609-1616.
15. Plevris JN, Haydon GH, Simpson KJ, Dawkes R, Ludlum CA, Harrison DJ, Hayes PC: Serum hyaluronate- a non-invasive test for diagnosis liver cirrhosis. Eur J Gastroenterol Hepatol 2000, 12:1121-1127.
16. Croquet V, Vuillemin E, Ternisien C, Pilette C, Oberti F, Gallois Y, Trossaert M, Rousselet MC, Chappard D, Cales P: Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol 2002, 14:1133-1141.
17. Cadranel JF, Mathurin P: Prothrombin index decrease: a useful and reliable marker of extensive fibrosis? Eur J Gastroenterol Hepatol 2002, 14:1057-1059.
18. Bramley PN, Rathbone BJ, Forbes MA, Cooper EH, Losowsky MS: Serum hyaluronate as a marker of hepatic derangement in acute liver damage. J Hepatol 1991, 13:8-13.
19. Nyberg A, Engstrom-Laurent A, Loof L: Serum hyaluronate in primary billiary cirrhosis- a biochemical marker for progressive liver disease. Hepatology 1988, 8:142-146.
20. Stickel F, Poseschl G, Schuppan D, Conradt C, Srrenge-Hesse A, Fuchs FS, Hofmann WJ, Seitz HK: Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur J Gatroenterol Hepatol 2003, 15:945-950.
21. Ishak K, Baptista A, Bianchi L, Callea F, Groote JD, Guadat F, Denk H, Desmet V, Korb G, MacSween RN, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H: Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
22. Wai CT, Greenson JK, Fonata RJ, Kalbflisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis B. Hepatology 2003, 38: 518-526.
23. Guechot J, Poupon RE, Giral P, Balkau B, Giboudeau J, Poupon R. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 1994, 20:388-393.
24. Imbert-Bismuth F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075.
25. Poynard T, Imbert-Bismut F, Ratizu V, Chevret S, Jardel J, Mossalli J. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002, 9:128-133.
26. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T: Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003, 39:222-230.
27. Meyer K, Plmer JW. The polysaccharide of the vitrous humor. J Biol Chem 1934, 107:629-634.
28. Laurent TC, Fraser JRE. The properties and turnover of hyaluronate. in: Ciba Foundation Symposium 124, ed Functions of proteoglycans, Chichester England Wiley, 1986:9-29.
29. Tamaki S, Ueno T, Torimura T, Sata M, Tanikawa K. Evaluation of hyaluronic acid binding ability of hepatic sinusoidal cells in rat liver with liver cirrhosis. Gastroenterology 1996, 111:1049-1057.
30. Smedsrod B, Pertoft H, Erikson S, Fraser RF, Laurent TC. Studies in vitro on the uptake and degradation of sodium hyaluronate in rat liver endothelial cells. Biochem J 1984, 223:617-626.
31. Truppe W, Basner R, Von Figura K, Kresse H. Uptake of hyaluronate by cultured cells. Biochem Biophys Res Commun 1977, 78:713-719.
32. Fraser JR, Laurent TC, Engstrom-Laurent A, Laurent UB. Elimination of hyaluronic acid from the blood stream in the human. Clin Exp Phrmacol Pyhsiol 1984, 11:17-25.
33. Tamaki S, Ueno T, Torimura T, Sata M, Tanikawa K. Evaluation of hyaluronic acid binding ability of hepatic sinusoidal cells in rat liver with liver cirrhosis. Gastroenterology 1996, 111:1049-1057.
34. Ueno T, Inuzuka S, Torimura T, Tamaki S, Kou H, Kin M, Minetoma T, Kimura Y, Ohira H, Sata M, Yoshida H, Tanikawa K: Serum hyaluronate reflects hepatic sinusoidal capilarization. Gastroenterology 1993, 105:475-481.
35. Gibson PR, Fraser JR, Brown JT, Finch CF, Jones PA, Colman JC, Dudley FJ. Hemodynamic and liver function predictors of serum hyaluronate in alcoholic liver disease. Hepatology 1992, 15:1054-1059.
36. Kojima H, Hongo Y, Harada H, Inouce T, Miyaji K, Kashiwagi M, Momose T, Arisaka Y, Fukui H, Murai S, Tokita H, Kamitsukasa H, Yagura M, Katsu K. Long-term histological prognosis and serum fibrosis marker in chronic hepatitis C patients treated with interferon. J Gastroenterol Hepatol 2001, 16:1015-1021.
37. Gressner AM, Schafer S. Comparison of sulphated glycosaminoglycan and hyaluronate synthesis and secretion in cultured hepatocyte, fat storing cells and kupffer cells. J Clin Chem Clin Biochem 1989, 27:141-149.
38. Engstrom-Laurent A, Feltelius N, Hallgren R, Wasteson A. Raised serum hyaluronate levels in scleroderma: an effect of growth factor induced activation of connective tissue cells. Ann Rheum Dis 1985, 44:614-620.
39. Hallengen R, Engstrom-Laurent A, Nisbeth U. Circulating hyaluronate potential marker of altered metabolism of the connective tissue in uremia. Nephron 1982, 46:150-154.
40. Laurent UB, Laurent TC. On the origin of serum hyaluronate in blood. Biochem Int 1981, 2:195-199.
41. Ding H, Chen Y, Feng X, Liu D, Wu A, Zhang L. Correlation between liver fibrosis stage and serum liver fibrosis markers in patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2001, 9:78-80.